文献速递胸部肿瘤

S-1对比多西他赛用于经治晚期NSCLC的随机对照试验

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
PubMed 文献 · Ann Oncol · 2017-01-01

该随机对照试验纳入1154例既往接受过铂类治疗的晚期NSCLC患者,1:1随机接受S-1或多西他赛治疗。S-1组和多西他赛组中位总生存分别为12.75个月和12.52个月(HR 0.945;95%CI 0.833-1.073;P=0.3818),HR的95%CI上限低于1.2,证实S-1不劣于多西他赛。两组无进展生存差异无统计学意义(HR 1.033;95%CI 0.913-1.168;P=0.6080)。

要点

  • S-1组中位OS 12.75个月 vs 多西他赛组12.52个月,HR 0.945(95%CI 0.833-1.073),非劣效成立。
  • 两组PFS差异无统计学意义(HR 1.033;95%CI 0.913-1.168;P=0.6080)。
  • S-1组EORTC QLQ-C30总体健康状况评分在多个时间点显著改善。

核心结论

  • S-1与多西他赛疗效相当,为既往接受过治疗的晚期NSCLC患者提供了一种治疗选择。

研究设计与样本

  • 随机对照试验,纳入1154例既往接受≥1种铂类方案治疗的晚期NSCLC患者,1:1随机分配至S-1组(577例)或多西他赛组(577例)。
  • 多西他赛给药方案:日本60 mg/m2,其他所有研究中心75 mg/m2,第1天给药,3周为一周期。
  • S-1给药方案:根据体表面积80-120 mg/天,第1-28天给药,6周为一周期。
  • 主要终点为总生存,非劣效界值为风险比(HR)1.2。

主要发现

  • S-1组和多西他赛组中位总生存分别为12.75个月和12.52个月(HR 0.945;95%CI 0.833-1.073;P=0.3818),HR的95%CI上限低于1.2,证实S-1不劣于多西他赛。
  • 两组无进展生存差异无统计学意义(HR 1.033;95%CI 0.913-1.168;P=0.6080)。
  • S-1组和多西他赛组缓解率分别为8.3%和9.9%。
  • S-1组EORTC QLQ-C30总体健康状况评分在多个时间点观察到显著改善。
  • S-1组最常见药物不良反应为食欲下降(50.4%)、恶心(36.4%)和腹泻(35.9%);多西他赛组为中性粒细胞减少(54.8%)、白细胞减少(43.9%)和脱发(46.6%)。

临床怎么用

  • 对于既往接受过铂类治疗的晚期NSCLC患者,S-1可作为与多西他赛疗效相当的治疗选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral 5-fluorouracil-based S-1 as second- or third-line therapy compared with standard docetaxel therapy in patients with advanced NSCLC. PATIENTS AND METHODS: Patients with advanced NSCLC previously treated with ≥1 platinum-based therapy were randomized 1 : 1 to docetaxel (60 mg/m2 in Japan, 75 mg/m2 at all other study sites; day 1 in a 3-week cycle) or S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle). The primary endpoint was overall survival. The non-inferiority margin was a hazard ratio (HR) of 1.2. RESULTS: A total of 1154 patients (577 in each arm) were enrolled, with balanced patient characteristics between the two arms. Median overall survival was 12.75 and 12.52 months in the S-1 and docetaxel arms, respectively [HR 0.945; 95% confidence interval (CI) 0.833-1.073; P = 0.3818]. The upper limit of 95% CI of HR fell below 1.2, confirming non-inferiority of S-1 to docetaxel. Difference in progression-free survival between treatments was not significant (HR 1.033; 95% CI 0.913-1.168; P = 0.6080). Response rate was 8.3% and 9.9% in the S-1 and docetaxel arms, respectively. Significant improvement was observed in the EORTC QLQ-C30 global health status over time points in the S-1 arm. The most common adverse drug reactions were decreased appetite (50.4%), nausea (36.4%), and diarrhea (35.9%) in the S-1 arm, and neutropenia (54.8%), leukocytopenia (43.9%), and alopecia (46.6%) in the docetaxel arm. CONCLUSION: S-1 is equally as efficacious as docetaxel and offers a treatment option for patients with previously treated advanced NSCLC. CLINICAL TRIAL NUMBER: Japan Pharmaceutical Information Center, JapicCTI-101155.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Nokihara H, Lu S, Mok TSK, et al. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol. 2017. PMID: 29045553. doi:10.1093/annonc/mdx419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。